S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30

Editas Medicine Stock Forecast, Price & News

+0.33 (+1.82%)
(As of 01/24/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
2.64 million shs
Average Volume
2.02 million shs
Market Capitalization
$1.26 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive EDIT News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

Editas Medicine logo

About Editas Medicine

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.


Editas Medicine (NASDAQ:EDIT) Hits New 12-Month Low at $19.89
January 19, 2022 |  americanbankingnews.com
Editas Medicine (NASDAQ:EDIT) Reaches New 52-Week Low at $22.58
January 13, 2022 |  americanbankingnews.com
Editas Medicine (NASDAQ:EDIT) Trading Down 5%
January 12, 2022 |  americanbankingnews.com
Editas Medicine (NASDAQ:EDIT) Trading 5.7% Higher
January 7, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$90.73 million
Book Value
$6.28 per share


Net Income
$-115.98 million
Net Margins
Pretax Margin




Free Float
Market Cap
$1.26 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.90 out of 5 stars

Medical Sector

747th out of 1,415 stocks

Biological Products, Except Diagnostic Industry

117th out of 206 stocks

Analyst Opinion: 3.1Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions

Is Editas Medicine a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 3 sell ratings, 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Editas Medicine stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View analyst ratings for Editas Medicine
or view top-rated stocks.

How has Editas Medicine's stock price been impacted by COVID-19?

Editas Medicine's stock was trading at $20.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EDIT stock has decreased by 8.8% and is now trading at $18.48.
View which stocks have been most impacted by COVID-19

When is Editas Medicine's next earnings date?

Editas Medicine is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Editas Medicine

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) released its quarterly earnings data on Monday, November, 8th. The company reported ($0.57) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.81) by $0.24. The company earned $6.20 million during the quarter, compared to analyst estimates of $4.92 million. Editas Medicine had a negative net margin of 871.91% and a negative trailing twelve-month return on equity of 38.28%. The company's revenue was down 90.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.12 earnings per share.
View Editas Medicine's earnings history

What price target have analysts set for EDIT?

13 brokers have issued 12 month target prices for Editas Medicine's stock. Their forecasts range from $20.00 to $80.00. On average, they anticipate Editas Medicine's stock price to reach $50.00 in the next year. This suggests a possible upside of 170.6% from the stock's current price.
View analysts' price targets for Editas Medicine
or view top-rated stocks among Wall Street analysts.

Who are Editas Medicine's key executives?

Editas Medicine's management team includes the following people:

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Square (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

When did Editas Medicine IPO?

(EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Exchange Traded Concepts LLC (0.08%), Cutler Group LP (0.00%), Green Alpha Advisors LLC (0.05%), Aries Wealth Management (0.04%), McGuire Investment Group LLC (0.03%) and Russell Investments Group Ltd. (0.03%). Company insiders that own Editas Medicine stock include Bruce Eaton, Charles Albright, Cynthia Collins, James C Mullen, Lisa Anne Michaels and Michelle Robertson.
View institutional ownership trends for Editas Medicine

Which institutional investors are selling Editas Medicine stock?

EDIT stock was sold by a variety of institutional investors in the last quarter, including XR Securities LLC, Russell Investments Group Ltd., and McGuire Investment Group LLC. Company insiders that have sold Editas Medicine company stock in the last year include Bruce Eaton, James C Mullen, Lisa Anne Michaels, and Michelle Robertson.
View insider buying and selling activity for Editas Medicine
or view top insider-selling stocks.

Which institutional investors are buying Editas Medicine stock?

EDIT stock was bought by a variety of institutional investors in the last quarter, including Aries Wealth Management, Exchange Traded Concepts LLC, Cutler Group LP, Green Alpha Advisors LLC, International Assets Investment Management LLC, Ahrens Investment Partners LLC, and Patriot Financial Group Insurance Agency LLC.
View insider buying and selling activity for Editas Medicine
or or view top insider-buying stocks.

How do I buy shares of Editas Medicine?

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $18.48.

How much money does Editas Medicine make?

Editas Medicine has a market capitalization of $1.26 billion and generates $90.73 million in revenue each year. The company earns $-115.98 million in net income (profit) each year or ($3.24) on an earnings per share basis.

How many employees does Editas Medicine have?

Editas Medicine employs 235 workers across the globe.

What is Editas Medicine's official website?

The official website for Editas Medicine is www.editasmedicine.com.

Where are Editas Medicine's headquarters?

Editas Medicine is headquartered at 11 Hurley Street, Cambridge MA, 02141.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at (617) 401-9000 or via email at [email protected].

This page was last updated on 1/25/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.